SCHEMBL2824779

SCHEMBL2824779

CCOC(=O)c1c(C=Cc2cccc(OC(F)F)c2O)nc2sccn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.48
TP53 P04637 2/20 0.36
MAPT P10636 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HTT P42858 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
RAB9A P51151 3/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
CASP3 P42574 1/20 0.35
KMT2A Q03164 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824778 1.00 MAPK1 (0.48) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2827316 0.86 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2822592 0.86 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2827313 0.86 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2822595 0.86 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2826793 0.85 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2826796 0.85 MAPK1 (0.43) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2823667 0.85 MAPK1 (0.51) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2823672 0.85 MAPK1 (0.51) MAPK1TP53MAPTL3MBTL1KDM4E
SCHEMBL2823943 0.84 MAPK1 (0.42) MAPK1TP53MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 MAPK1 2141/4885TP53 4336/4885MAPT 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.